Subtopic Deep Dive

Hop Compounds Angiogenesis Inhibition
Research Guide

Q: What defines hop compounds angiogenesis inhibition?

It examines xanthohumol and prenylflavonoids from hops suppressing VEGF signaling and endothelial tube formation in cancer models via NF-κB inhibition (Liu et al., 2015).

Q: What are key methods used?

In vitro HUVEC proliferation/tube formation assays, NF-κB luciferase reporters, and in vivo Matrigel plug or TRAMP mouse models measure anti-angiogenic activity (Saito et al., 2017; Venè et al., 2012).

Q: What are the most cited papers?

Liu et al. (2015, 238 citations) profiles xanthohumol pharmacology; Harikumar et al. (2008, 163 citations) details NF-κB cysteine modification; Saito et al. (2017, 117 citations) shows pancreatic cancer effects.

Q: What open problems exist?

Improving xanthohumol bioavailability for systemic use and validating human endothelial targets beyond mouse models remain unsolved (Costa et al., 2013; Dell’Eva et al., 2007).

What is Hop Compounds Angiogenesis Inhibition?

Hop compounds angiogenesis inhibition studies the anti-angiogenic effects of xanthohumol and prenylflavonoids from hops (Humulus lupulus) on VEGF signaling, endothelial cell proliferation, and tube formation in cancer models.

Xanthohumol suppresses NF-κB activation to inhibit angiogenesis in pancreatic and hematologic cancers (Saito et al., 2017; Dell’Eva et al., 2007). In vitro assays show reduced endothelial proliferation and invasion, with in vivo models confirming tumor growth limitation (Harikumar et al., 2008; Venè et al., 2012). Over 10 key papers since 2007 document these mechanisms, with Liu et al. (2015) providing a pharmacological profile (238 citations).

Curated Papers

Key Challenges

Why It Matters

Xanthohumol inhibits angiogenesis in pancreatic cancer by suppressing NF-κB, reducing VEGF expression and tube formation in HUVEC assays (Saito et al., 2017, 117 citations). In hematologic malignancies, it targets AKT/NF-κB pathways to block endothelial sprouting and leukemia progression (Dell’Eva et al., 2007, 76 citations). These effects offer adjunctive cancer therapies, modulating tumor microenvironments and wound healing in diabetic models (Costa et al., 2013, 81 citations). Applications extend to preventing metastasis in prostate and colorectal cancers (Venè et al., 2012; Liu et al., 2019).

Key Research Challenges

NF-κB Pathway Specificity

Distinguishing xanthohumol's NF-κB inhibition from off-target effects remains difficult in complex tumor models (Harikumar et al., 2008). Saito et al. (2017) noted variable suppression in pancreatic cells requiring higher doses. Clinical translation needs isoform-specific assays.

In Vivo Bioavailability Limits

Poor oral bioavailability hinders systemic anti-angiogenic effects despite strong in vitro data (Liu et al., 2015). Costa et al. (2013) showed topical efficacy in diabetic wounds but systemic tumors demand formulation advances. Nanoparticle delivery is underexplored.

Endothelial Target Validation

Confirming direct VEGF suppression versus indirect inflammation modulation challenges assays (Dell’Eva et al., 2007). Venè et al. (2012) used TRAMP mice but lacked human endothelial correlates. Co-culture models are needed for tube formation metrics.

Essential Papers

Pharmacological Profile of Xanthohumol, a Prenylated Flavonoid from Hops (Humulus lupulus)

Ming Liu, Poul Erik Hansen, Genzhu Wang et al. · 2015 · Molecules · 238 citations

The female inflorescences of hops (Humulus lupulus L.), a well-known bittering agent used in the brewing industry, have long been used in traditional medicines. Xanthohumol (XN) is one of the bioac...

Modification of the cysteine residues in IκBα kinase and NF-κB (p65) by xanthohumol leads to suppression of NF-κB–regulated gene products and potentiation of apoptosis in leukemia cells

Kuzhuvelil B. Harikumar, Ajaikumar B. Kunnumakkara, Kwang Seok Ahn et al. · 2008 · Blood · 163 citations

Xanthohumol (XN), a prenylated chalcone isolated from hop plant, exhibits anti-inflammatory, antiproliferative, and antiangiogenic properties through an undefined mechanism. Whether examined by int...

Xanthohumol inhibits angiogenesis by suppressing nuclear factor‐κB activation in pancreatic cancer

Kenta Saito, Yoichi Matsuo, Hiroyuki Imafuji et al. · 2017 · Cancer Science · 117 citations

Xantohumol, a prenylated chalcone from hops ( Humulus lupulus L.), has been shown to inhibit proliferation in some cancers. However, little is known regarding the effects of xanthohumol in pancreat...

An Update on Antitumor Activity of Naturally Occurring Chalcones

En-Hui Zhang, Rufeng Wang, Shuzhen Guo et al. · 2013 · Evidence-based Complementary and Alternative Medicine · 93 citations

Chalcones, which have characteristic 1,3-diaryl-2-propen-1-one skeleton, are mainly produced in roots, rhizomes, heartwood, leaves, and seeds of genera Angelica, Sophora, Glycyrrhiza, Humulus, Scut...

Xanthohumol from Hop: Hope for cancer prevention and treatment

Sosmitha Girisa, Queen Saikia, Devivasha Bordoloi et al. · 2021 · IUBMB Life · 86 citations

Abstract Cancer is a major public health concern due to high mortality and poor quality of life of patients. Despite the availability of advanced therapeutic interventions, most treatment modalitie...

Xanthohumol Modulates Inflammation, Oxidative Stress, and Angiogenesis in Type 1 Diabetic Rat Skin Wound Healing

Raquel Costa, Rita Negrão, Inês M. Valente et al. · 2013 · Journal of Natural Products · 81 citations

Type 1 diabetes mellitus is responsible for metabolic dysfunction, accompanied by chronic inflammation, oxidative stress, and endothelium dysfunction, and is often associated with impaired wound he...

Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis

Wenbin Liu, Wei Li, Haidan Liu et al. · 2019 · International Journal of Biological Sciences · 80 citations

Deregulation of glycolysis is a common phenomenon in human colorectal cancer (CRC). In the present study, we reported that Hexokinase 2 (HK2) is overexpressed in human CRC tissues and cell lines, k...

Reading Guide

Foundational Papers

Start with Harikumar et al. (2008, 163 citations) for NF-κB mechanisms in leukemia angiogenesis, then Dell’Eva et al. (2007, 76 citations) for AKT inhibition in hematologic models, and Liu et al. (2015, 238 citations) for comprehensive pharmacology.

Recent Advances

Study Saito et al. (2017, 117 citations) for pancreatic cancer specifics and Girisa et al. (2021, 86 citations) for prevention potential; Liu et al. (2019, 80 citations) updates glycolysis links.

Core Methods

Core techniques include HUVEC Matrigel tube formation assays, NF-κB p65 nuclear translocation via Western blot, VEGF ELISA quantification, and in vivo aortic ring sprouting models (Saito et al., 2017; Costa et al., 2013).

How PapersFlow Helps You Research Hop Compounds Angiogenesis Inhibition

Discover & Search

Research Agent uses searchPapers('xanthohumol angiogenesis inhibition') to retrieve Liu et al. (2015) with 238 citations, then citationGraph to map NF-κB clusters from Harikumar et al. (2008) and Saito et al. (2017), and findSimilarPapers for prenylflavonoid extensions.

Analyze & Verify

Analysis Agent applies readPaperContent on Saito et al. (2017) to extract HUVEC tube formation data, verifyResponse with CoVe against Harikumar et al. (2008) for NF-κB consistency, and runPythonAnalysis to plot IC50 doses from 5 papers using pandas for statistical verification (p<0.05 via t-test). GRADE grading scores mechanisms as high-evidence from in vivo models.

Synthesize & Write

Synthesis Agent detects gaps in bioavailability studies across Dell’Eva et al. (2007) and Costa et al. (2013), flags NF-κB contradictions, and generates exportMermaid diagrams of VEGF pathways. Writing Agent uses latexEditText for figure captions, latexSyncCitations to integrate 10 papers, and latexCompile for a review manuscript.

Use Cases

"Compare IC50 values of xanthohumol on HUVEC proliferation across papers."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of doses from Saito 2017, Harikumar 2008) → matplotlib dose-response plot output.

"Draft LaTeX section on xanthohumol NF-κB inhibition in pancreatic cancer."

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Saito 2017, Liu 2015) → latexCompile → PDF with pathway figure.

"Find code for xanthohumol glycolysis assays in colorectal cancer models."

Research Agent → paperExtractUrls (Liu 2019) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R script for HK2 knockdown analysis.

Automated Workflows

Deep Research workflow scans 50+ OpenAlex papers on 'xanthohumol NF-κB angiogenesis', chains citationGraph → readPaperContent → GRADE report on evidence strength. DeepScan applies 7-step CoVe to validate Dell’Eva et al. (2007) claims against in vivo data. Theorizer generates hypotheses linking xanthohumol bioavailability to tumor suppression from Costa et al. (2013).

Try Doxa for Hop Compounds Angiogenesis Inhibition Research

Frequently Asked Questions

What defines hop compounds angiogenesis inhibition?

It examines xanthohumol and prenylflavonoids from hops suppressing VEGF signaling and endothelial tube formation in cancer models via NF-κB inhibition (Liu et al., 2015).

What are key methods used?

In vitro HUVEC proliferation/tube formation assays, NF-κB luciferase reporters, and in vivo Matrigel plug or TRAMP mouse models measure anti-angiogenic activity (Saito et al., 2017; Venè et al., 2012).

What are the most cited papers?

Liu et al. (2015, 238 citations) profiles xanthohumol pharmacology; Harikumar et al. (2008, 163 citations) details NF-κB cysteine modification; Saito et al. (2017, 117 citations) shows pancreatic cancer effects.

What open problems exist?

Improving xanthohumol bioavailability for systemic use and validating human endothelial targets beyond mouse models remain unsolved (Costa et al., 2013; Dell’Eva et al., 2007).